8% Off
Ajuben6 mg
Incepta Pharmaceuticals Ltd.
৳644.00
Add to cart
Generic medicine
Deutetrabenazine: Brands, Price & Uses in Bangladesh
Deutetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for use in adults for the following FDA-approved (established) indications: Chorea associated with Huntington's…
About Deutetrabenazine
Indications of Deutetrabenazine
Deutetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for use in adults for the following FDA-approved (established) indications:
- Chorea associated with Huntington's disease — reduces involuntary, dance-like movements.
- Tardive dyskinesia — reduces repetitive, involuntary movements (typically of the face, tongue, or limbs) caused by long-term use of dopamine-receptor-blocking drugs such as antipsychotics.
Deutetrabenazine has also been studied in small clinical trials for other hyperkinetic movement disorders (for example, tic disorders such as Tourette syndrome); this is considered off-label use and is not an FDA-approved indication, so it should only be considered under specialist supervision.
Deutetrabenazine does not cure the underlying disease; it manages the movement symptoms.
Dosage & Administration of Deutetrabenazine
Dosing of Deutetrabenazine is individualized and must be titrated slowly by a physician according to response and tolerability. Typical adult titration schedules are summarized below; exact starting products/strengths (immediate-release vs. extended-release) and titration pace should follow the prescribing physician's instructions.
| Indication | Starting dose | Titration | Usual maximum dose |
|---|---|---|---|
| Chorea associated with Huntington's disease | 6 mg once daily (immediate-release) or 12 mg once daily (extended-release) | Increase gradually at weekly intervals as needed and tolerated, in small increments, guided by chorea control and side effects | Up to 48 mg/day (lower caps apply with strong CYP2D6 inhibitors or in known CYP2D6 poor metabolizers — see Interactions) |
| Tardive dyskinesia | 6 mg twice daily (immediate-release) or 12 mg once daily (extended-release) | Increase gradually at weekly intervals as needed and tolerated | Up to 48 mg/day (lower caps apply as above) |
Deutetrabenazine should be taken with food. Extended-release tablets must be swallowed whole and must not be crushed, chewed, or split. Immediate-release doses of more than 6 mg/day are usually given in divided doses. If a dose is missed, it should generally be skipped rather than doubled at the next scheduled time — the prescribing physician's specific instructions should be followed. Do not stop Deutetrabenazine abruptly without medical advice, as chorea or dyskinesia may worsen.
Side Effects of Deutetrabenazine
Common side effects of Deutetrabenazine include somnolence/drowsiness, diarrhea, dry mouth, fatigue, insomnia, and nasopharyngitis (common cold-type symptoms).
Serious side effects (require prompt medical attention) include:
- New or worsening depression, or suicidal thoughts/behavior (boxed warning in Huntington's disease patients — see Precautions).
- Parkinsonism (slowness, rigidity, tremor) and akathisia (inner restlessness), which are dose-related.
- Neuroleptic malignant syndrome (rare but potentially life-threatening — fever, muscle rigidity, altered consciousness, autonomic instability), especially with concurrent dopamine-blocking drugs.
- QT interval prolongation at higher doses, which can predispose to serious irregular heart rhythms.
- Sedation severe enough to impair driving or operating machinery.
Contraindications of Deutetrabenazine
Deutetrabenazine is contraindicated in the following situations:
- Known hypersensitivity to Deutetrabenazine or any component of the formulation.
- Patients with hepatic impairment (of any degree).
- Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping an MAOI.
- Concomitant use of reserpine, or use within 20 days of stopping reserpine.
- Concomitant use of tetrabenazine or valbenazine (other VMAT2 inhibitors).
- Huntington's disease patients who are actively suicidal, or who have untreated or inadequately treated depression.
- Congenital long QT syndrome, or a history of cardiac arrhythmias associated with QT-prolonging medicines, when Deutetrabenazine is to be used at higher doses.
Frequently Asked Questions about Deutetrabenazine
What is Deutetrabenazine used for?
Deutetrabenazine is used in adults to reduce involuntary movements — specifically chorea associated with Huntington's disease and tardive dyskinesia caused by long-term antipsychotic use. It controls symptoms but does not cure the underlying condition.
Can Deutetrabenazine cause depression or suicidal thoughts?
Yes. In patients with Huntington's disease, Deutetrabenazine carries a boxed warning because it can increase the risk of depression and suicidal thoughts or behavior. Patients and caregivers should watch for mood changes, agitation, or suicidal thoughts and report them to a doctor immediately. Deutetrabenazine should not be used in Huntington's disease patients with untreated depression or active suicidal ideation.
Who should not take Deutetrabenazine?
Deutetrabenazine should not be used by anyone with hepatic (liver) impairment, anyone taking an MAOI or reserpine (or within the required washout periods), anyone also taking tetrabenazine or valbenazine, Huntington's disease patients with untreated depression or active suicidal ideation, or patients with congenital long QT syndrome or a history of arrhythmia linked to QT-prolonging drugs when higher doses are used.
Is Deutetrabenazine safe during pregnancy or breastfeeding?
Animal studies suggest Deutetrabenazine may cause fetal harm, and there isn't enough human data to confirm safety in pregnancy. It should be used in pregnancy only if clearly needed and the benefit outweighs the potential risk, and only under a physician's guidance. It is also not known whether Deutetrabenazine passes into breast milk, so a doctor should help decide whether to continue breastfeeding or continue the medicine.
What are the most common side effects of Deutetrabenazine?
The most common side effects are sleepiness/drowsiness, diarrhea, dry mouth, fatigue, and insomnia. More serious but less common effects include worsening parkinsonism, restlessness (akathisia), neuroleptic malignant syndrome, and QT interval prolongation at higher doses — these need prompt medical review.
What should I do if I miss a dose or take too much Deutetrabenazine?
If a dose is missed, follow the prescribing physician's specific instructions rather than doubling the next dose. If an overdose is suspected — with symptoms such as severe sedation, dystonia, confusion, or fainting — seek immediate medical attention or contact a poison control center right away; there is no specific antidote, so treatment is supportive in a medical setting.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.